Search engine finds info for practicing physicians

Share this article:
Pharma marketers now have an added opportunity to connect with healthcare professionals with the debut of an innovative search engine designed by CMPMedica.

The new site, at SearchMedica.com, will offer vertical or topic-specific search engines for doctors and other health professionals. Unbiased search results will contain well-known journals, peer-reviewed research and articles for healthcare professionals.

At press time, the site was in its first phase of roll-out, offering  search capabilities specializing in psychiatry.

Similar search engines focused on primary care, oncology and other specialties will debut in 2007, CMPMedica's senior product manager Cyndy Finnie told MM&M.

“While Google goes out and crawls all of the Internet, SearchMedica.com crawls the Web sites that are of most interest to practicing doctors.” Finnie explained.

The site is free and available to all healthcare professionals and will be supported by ads, offering opportunities to marketers seeking to reach a health professional audience, Finnie said.

“We are using a hybrid model that's a combination of sponsorship and performance,” she said. “So, for example, a pharmaceutical company has the opportunity to own a category or therapeutic area exclusively or share the real estate.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.